Pharma May See Brighter Enforcement Environment After US Justice Department Policy Changes
Policy revisions on individual liability for corporate misconduct, noncompliance with agency guidance documents and dismissal of False Claims Act cases suggest a greater willingness by DoJ leadership to reconsider arguments often raised by life sciences companies, attorneys say at a Food and Drug Law Institute conference.
You may also be interested in...
US FDA's Rush Following Novartis' Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation
Early release of inspection findings is unusual, signaling likelihood that Novartis will face tough scrutiny of its actions, and perhaps stiff fines because of the fraud.
Justice Department lacks absolute right to dismiss meritorious qui tam complaints filed by affiliates of National Healthcare Analysis Group against numerous pharmaceutical companies, whistleblowers say, taking issue with government’s “personal attacks” on their business model and research practices.
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.